Published in Brain Res Mol Brain Res on May 01, 1997
Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann N Y Acad Sci (2010) 2.36
Gene expression profile of the nucleus accumbens of human cocaine abusers: evidence for dysregulation of myelin. J Neurochem (2004) 1.82
The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Brain Res Rev (2005) 1.80
Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci (2012) 1.48
Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse (2005) 1.43
Behavioral sensitization to cocaine in rats: evidence for temporal differences in dopamine D3 and D2 receptor sensitivity. Psychopharmacology (Berl) (2011) 1.18
Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [11C]-+-PHNO. Neuropsychopharmacology (2013) 1.16
Gene expression profiling in the brains of human cocaine abusers. Addict Biol (2005) 1.07
Behavioral sensitization, alternative splicing, and d3 dopamine receptor-mediated inhibitory function. Neuropsychopharmacology (2006) 0.99
The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access. Addict Biol (2010) 0.98
The dopamine D3 receptor partial agonist CJB 090 inhibits the discriminative stimulus but not the reinforcing or priming effects of cocaine in squirrel monkeys. Psychopharmacology (Berl) (2009) 0.96
Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design. Adv Pharmacol (2014) 0.95
Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.93
Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment. Psychopharmacology (Berl) (2010) 0.90
The functional DRD3 Ser9Gly polymorphism (rs6280) is pleiotropic, affecting reward as well as movement. PLoS One (2013) 0.88
Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis. J Med Chem (2015) 0.88
Unpredictable saccharin reinforcement enhances locomotor responding to amphetamine. Behav Brain Res (2011) 0.87
Differential effects of the dopamine D3 receptor antagonist PG01037 on cocaine and methamphetamine self-administration in rhesus monkeys. Neuropharmacology (2015) 0.87
Dopamine D3 and 5-HT1B receptor dysregulation as a result of psychostimulant intake and forced abstinence: Implications for medications development. Neuropharmacology (2013) 0.85
Neurotensin gene expression and behavioral responses following administration of psychostimulants and antipsychotic drugs in dopamine D(3) receptor deficient mice. Neuropsychopharmacology (2001) 0.83
Neuronal circuitry underlying the impact of D3 receptor ligands in drug addiction. Eur Neuropsychopharmacol (2014) 0.83
Molecular characterization of individual D3 dopamine receptor-expressing cells isolated from multiple brain regions of a novel mouse model. Brain Struct Funct (2012) 0.82
Dopamine D3 receptor is necessary for ethanol consumption: an approach with buspirone. Neuropsychopharmacology (2014) 0.80
Phenylpiperazine derivatives with selectivity for dopamine D3 receptors modulate cocaine self-administration in rats. Neuropharmacology (2012) 0.80
High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice. J Med Chem (2015) 0.79
Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats. Behav Pharmacol (2012) 0.79
The brain gene expression profile of dopamine D2/D3 receptors and associated signaling proteins following amphetamine self-administration. Neuroscience (2015) 0.78
Further characterization of quinpirole-elicited yawning as a model of dopamine D3 receptor activation in male and female monkeys. J Pharmacol Exp Ther (2014) 0.78
Reduction of cocaine self-administration and D3 receptor-mediated behavior by two novel dopamine D3 receptor-selective partial agonists, OS-3-106 and WW-III-55. J Pharmacol Exp Ther (2013) 0.78
Functional and structural brain changes associated with methamphetamine abuse. Brain Sci (2012) 0.77
Current perspectives on the neurobiology of drug addiction: a focus on genetics and factors regulating gene expression. ISRN Neurol (2012) 0.76
Making Sense of: Sensitization in Schizophrenia. Int J Neuropsychopharmacol (2016) 0.76
Dopamine D3 receptor-preferring agonist enhances the subjective effects of cocaine in humans. Psychiatry Res (2015) 0.75
Fos expression in response to dopamine D3-preferring phenylpiperazine drugs given with and without cocaine. Synapse (2013) 0.75
Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology (1988) 4.28
A direct repeat is a hotspot for large-scale deletion of human mitochondrial DNA. Science (1989) 3.02
Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol (1998) 2.92
MELAS: clinical features, biochemistry, and molecular genetics. Ann Neurol (1992) 2.48
Inactivation of human immunodeficiency virus-1 at short time intervals using undiluted bleach. J Acquir Immune Defic Syndr (1993) 2.36
Recombination via flanking direct repeats is a major cause of large-scale deletions of human mitochondrial DNA. Nucleic Acids Res (1990) 2.28
Mitochondrial function in heart muscle from patients with idiopathic dilated cardiomyopathy. Cardiovasc Res (2000) 2.26
Cytochrome c oxidase assembly in primates is sensitive to small evolutionary variations in amino acid sequence. Mol Biol Evol (2000) 2.19
Distribution of wild-type and common deletion forms of mtDNA in normal and respiration-deficient muscle fibers from patients with mitochondrial myopathy. Hum Mol Genet (1994) 2.16
Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet (1991) 2.10
Widespread tissue distribution of mitochondrial DNA deletions in Kearns-Sayre syndrome. Neurology (1990) 1.97
An out-of-frame cytochrome b gene deletion from a patient with parkinsonism is associated with impaired complex III assembly and an increase in free radical production. Ann Neurol (2000) 1.95
Titrating the effects of mitochondrial complex I impairment in the cell physiology. J Biol Chem (1999) 1.92
Mitochondrial encephalomyopathies. Arch Neurol (1993) 1.79
Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci (1996) 1.78
Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease. Acta Neurol Scand (2009) 1.75
Lack of oxidative phosphorylation and low mitochondrial membrane potential decrease susceptibility to apoptosis and do not modulate the protective effect of Bcl-x(L) in osteosarcoma cells. J Biol Chem (2000) 1.55
Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol (1999) 1.55
Reactive oxygen species and mitochondrial diseases. Semin Cell Dev Biol (2001) 1.53
Frequency and type of electrocardiographic abnormalities in cocaine abusers (electrocardiogram in cocaine abuse). Am J Cardiol (1994) 1.53
Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies. Ann Neurol (1991) 1.49
Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity. J Forensic Sci (1997) 1.43
Transcription and translation of deleted mitochondrial genomes in Kearns-Sayre syndrome: implications for pathogenesis. Am J Hum Genet (1990) 1.40
Human xenomitochondrial cybrids. Cellular models of mitochondrial complex I deficiency. J Biol Chem (1998) 1.38
Manipulating mitochondrial DNA heteroplasmy by a mitochondrially targeted restriction endonuclease. Hum Mol Genet (2001) 1.32
Expanding the functional human mitochondrial DNA database by the establishment of primate xenomitochondrial cybrids. Proc Natl Acad Sci U S A (1997) 1.31
Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med (2013) 1.31
Catechols in post-mortem brain of patients with Parkinson disease. Eur J Neurol (2010) 1.30
Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol (1997) 1.27
Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann Neurol (1997) 1.27
Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science (1985) 1.26
Detection of HIV-1 DNA in needle/syringes, paraphernalia, and washes from shooting galleries in Miami: a preliminary laboratory report. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.24
High affinity cocaine recognition sites on the dopamine transporter are elevated in fatal cocaine overdose victims. J Pharmacol Exp Ther (1994) 1.21
MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy. Neurology (2011) 1.19
Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol (1999) 1.19
Preliminary laboratory studies of inactivation of HIV-1 in needles and syringes containing infected blood using undiluted household bleach. J Acquir Immune Defic Syndr (1994) 1.18
Suppression of a mitochondrial tRNA gene mutation phenotype associated with changes in the nuclear background. Hum Mol Genet (1999) 1.17
A new mtDNA mutation in the tRNA(Lys) gene associated with myoclonic epilepsy and ragged-red fibers (MERRF). Am J Hum Genet (1992) 1.16
Extremely high levels of mutant mtDNAs co-localize with cytochrome c oxidase-negative ragged-red fibers in patients harboring a point mutation at nt 3243. Hum Mol Genet (1994) 1.15
Mitochondrial DNA depletion: mutations in thymidine kinase gene with myopathy and SMA. Neurology (2002) 1.14
Psychotic symptoms in Parkinson's disease. From description to etiology. J Neurol (2005) 1.14
Immunocytochemical study of dystrophin in muscle cultures from patients with Duchenne muscular dystrophy and unaffected control patients. Am J Pathol (1988) 1.14
Autoradiographic localization of M1 and M2 muscarine receptors in the rat brain. Neuroscience (1986) 1.13
Functional constraints of nuclear-mitochondrial DNA interactions in xenomitochondrial rodent cell lines. J Biol Chem (2000) 1.13
Segregation patterns of a novel mutation in the mitochondrial tRNA glutamic acid gene associated with myopathy and diabetes mellitus. Am J Hum Genet (1995) 1.12
Mitochondrial myopathy of childhood associated with depletion of mitochondrial DNA. Neurology (1992) 1.10
Pathophysiology and fate of hepatocytes in a mouse model of mitochondrial hepatopathies. Gut (2007) 1.09
Cloning of an endangered species (Bos gaurus) using interspecies nuclear transfer. Cloning (2000) 1.09
The mitochondrial tRNA(Leu)(UUR)) mutation in MELAS: a model for pathogenesis. Biochim Biophys Acta (1992) 1.08
A disease-associated G5703A mutation in human mitochondrial DNA causes a conformational change and a marked decrease in steady-state levels of mitochondrial tRNA(Asn). Mol Cell Biol (1997) 1.08
Organ-specific shifts in mtDNA heteroplasmy following systemic delivery of a mitochondria-targeted restriction endonuclease. Gene Ther (2010) 1.06
Purification and substrate specificity of heparitinase I and heparitinase II from Flavobacterium heparinum. Analyses of the heparin and heparan sulfate degradation products by 13C NMR spectroscopy. J Biol Chem (1990) 1.06
Manipulation of mtDNA heteroplasmy in all striated muscles of newborn mice by AAV9-mediated delivery of a mitochondria-targeted restriction endonuclease. Gene Ther (2011) 1.04
A new mutation associated with MELAS is located in a mitochondrial DNA polypeptide-coding gene. Neuromuscul Disord (1995) 1.04
Cocaethylene: a unique cocaine metabolite displays high affinity for the dopamine transporter. J Neurochem (1991) 1.03
Modulating mtDNA heteroplasmy by mitochondria-targeted restriction endonucleases in a 'differential multiple cleavage-site' model. Gene Ther (2007) 1.02
Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem (1995) 1.01
Pharmacokinetics of Hoasca alkaloids in healthy humans. J Ethnopharmacol (1999) 0.99
Differential cholinergic innervation within functional subdivisions of the human cerebral cortex: a choline acetyltransferase study. J Comp Neurol (1992) 0.99
Localization of nerve growth factor receptors in cholinergic neurons of the human basal forebrain. Neurosci Lett (1986) 0.98
Neurofibrillary tangles in cholinergic pedunculopontine neurons in Alzheimer's disease. Ann Neurol (1988) 0.97
DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function. J Med Genet (2004) 0.97
Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra. J Comp Neurol (1999) 0.95
New morphological approaches to the study of mitochondrial encephalomyopathies. Brain Pathol (1992) 0.95
Response of F344 rats to inhalation of subclinical levels of sarin: exploring potential causes of Gulf War illness. Toxicol Ind Health (2001) 0.94
Kappa2 opioid receptors in limbic areas of the human brain are upregulated by cocaine in fatal overdose victims. J Neurosci (1997) 0.94
Radioligand binding and immunoautoradiographic evidence for a lack of toxicity to dopaminergic nerve terminals in human cocaine overdose victims. Brain Res (1997) 0.94
Dopamine transporter DAT and receptor DRD2 variants affect risk of lethal cocaine abuse: a gene-gene-environment interaction. Transl Psychiatry (2013) 0.94
Vesicular acetylcholine transporter density and Alzheimer's disease. Neurobiol Aging (1997) 0.92
Cytosolic proteomic alterations in the nucleus accumbens of cocaine overdose victims. Mol Psychiatry (2006) 0.91
Dopamine D(1) receptor expression in human basal ganglia and changes in Parkinson's disease. Brain Res Mol Brain Res (2001) 0.90
Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca. J Anal Toxicol (1996) 0.89
Characterization of L-[3H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal. J Neurochem (1986) 0.89
Rho(0) tumor cells: a model for studying whether mitochondria are targets for rhodamine 123, doxorubicin, and other drugs. Biochem Pharmacol (2000) 0.89
Mitochondrial encephalomyopathies. Neurol Clin (1990) 0.88
Localization of nerve growth factor receptors in the normal human brain and in Alzheimer's disease. Neurobiol Aging (1989) 0.88
Clinical and morphologic features of a myopathy associated with a point mutation in the mitochondrial tRNA(Pro) gene. Neurology (1994) 0.88
Cocaethylene is more potent than cocaine in mediating lethality. Pharmacol Biochem Behav (1991) 0.88
High levels of mitochondrial DNA with an unstable 260-bp duplication in a patient with a mitochondrial myopathy. Neurology (1995) 0.88
Identification of a mutation in the mitochondrial tRNA(Cys) gene associated with mitochondrial encephalopathy. Hum Mutat (1996) 0.87
Deletions of mitochondrial DNA in Kearns-Sayre syndrome. 1988. Neurology (1998) 0.87
Effects of post-mortem delay on subunits of ionotropic glutamate receptors in human brain. Brain Res Mol Brain Res (2000) 0.87
Deletion of mitochondrial DNA in patients with combined features of Kearns-Sayre and MELAS syndromes. Ann Neurol (1991) 0.87
Structural and functional mitochondrial abnormalities associated with high levels of partially deleted mitochondrial DNAs in somatic cell hybrids. Somat Cell Mol Genet (1992) 0.86
Cholinergic innervation of the amygdaloid complex in the human brain and its alterations in old age and Alzheimer's disease. J Comp Neurol (1993) 0.86
Somatic sensory projections to the pretectum in the cat. Brain Res (1978) 0.86
Visualizing dopamine and serotonin transporters in the human brain with the potent cocaine analogue [125I]RTI-55: in vitro binding and autoradiographic characterization. J Neurochem (1994) 0.86
Characterization of kappa1-opioid receptor binding in human insular cortex. Life Sci (1999) 0.85
In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. J Pharmacol Exp Ther (2001) 0.85
Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine. Drug Metab Dispos (1998) 0.84
Drug interactions with the dopamine transporter in cryopreserved human caudate. J Pharmacol Exp Ther (2001) 0.84
Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. J Neural Transm (Vienna) (2003) 0.84
Detection and analysis of mitochondrial DNA deletions by whole genome PCR. Biochem Mol Med (1996) 0.84
Disorders associated with depletion of mitochondrial DNA. Brain Pathol (1992) 0.84
A MERRF/PEO overlap syndrome associated with the mitochondrial DNA 3243 mutation. Neurology (1996) 0.83
Interactions of cocaine with primary and secondary recognition sites on muscarinic receptors. Mol Pharmacol (1992) 0.83
Mapping dopamine transporters in the human brain with novel selective cocaine analog [125I]RTI-121. Synapse (1995) 0.83
Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease? Acta Neurol Scand (2005) 0.83